Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learningDaichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Cancer Science|December 11, 2025
Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, et al.
Anticancer Research|February 11, 2015
Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastasesAkito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
JTO Clinical and Research Reports|May 8, 2025
Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019LHideyuki Harada, Akito Hata, Masahiro Konno, et al.
Cancer Medicine|November 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620LTakehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, et al.
Cancer|October 10, 2013
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populationsAkito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Cancer Science|November 30, 2019
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancerShinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, et al.
JTO Clinical and Research Reports|August 2, 2024
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAILShigehiro Yagishita, Yasushi Goto, Makoto Nishio, et al.
JTO Clinical and Research Reports|February 11, 2022
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLCDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
JTO Clinical and Research Reports|April 10, 2023
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)Satoru Miura, Makoto Nishio, Hiroaki Akamatsu, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learningDaichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Cancer Science|December 11, 2025
Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, et al.
Anticancer Research|February 11, 2015
Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastasesAkito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
JTO Clinical and Research Reports|May 8, 2025
Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019LHideyuki Harada, Akito Hata, Masahiro Konno, et al.
Cancer Medicine|November 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620LTakehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, et al.
Cancer|October 10, 2013
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populationsAkito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Cancer Science|November 30, 2019
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancerShinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, et al.
JTO Clinical and Research Reports|August 2, 2024
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAILShigehiro Yagishita, Yasushi Goto, Makoto Nishio, et al.
JTO Clinical and Research Reports|February 11, 2022
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLCDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
JTO Clinical and Research Reports|April 10, 2023
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)Satoru Miura, Makoto Nishio, Hiroaki Akamatsu, et al.
Pageof 15